This international, peer-reviewed Open Access journal by Dove Medical Press focuses on the design and development of drugs, as well as the clinical outcomes, patient safety, and programs targeted at the effective and safe use of medicines. Sign up for email alerts here.
88,007 Monthly downloads/views I 4.319 Impact Factor I 6.6 CiteScore I 1.12 Source Normalized Impact per Paper (SNIP) I 0.784 Scimago Journal & Country Rank (SJR)
Record: found
Abstract: found
Article: found
Is Open Access
Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Purpose
Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer (NSCLC).
To overcome drug resistance and severe toxicities in the clinical application, redox-responsive
and pH-sensitive nanoparticle drug delivery systems were designed for the encapsulation
of ETB.
Methods
Poly(acrylic acid)-cystamine-oleic acid (PAA-ss-OA) was synthesized. PAA-ss-OA-modified
ETB-loaded lipid nanoparticles (PAA-ETB-NPs) were prepared using the emulsification
and solvent evaporation method. The tumor inhibition efficacy of PAA-ETB-NPs was compared
with that of ETB-loaded lipid nanoparticles (ETB-NPs) and free ETB anticancer drugs
in tumor-bearing mice.
Results
PAA-ETB-NPs had a size of 170 nm, with a zeta potential of −32 mV. The encapsulation
efficiency and drug loading capacity of PAA-ETB-NPs were over 85% and 2.6%, respectively.
In vitro cytotoxicity of ETB-NPs were higher than that of ETB solution. The cytotoxicity
of PAA-ETB-NPs was the highest. The in vivo tumor growth inhibition by PAA-ETB-NP
treatment was significantly higher than that by ETB-NPs and ETB solution. No obvious
weight loss was observed in any of the treatment groups, indicating that all the treatments
were well tolerated.
Conclusion
PAA-ETB-NPs could enhance the stability and anti-cancer ability of ETB to treat lung
cancer and are a promising drug delivery system for lung cancer treatment.
Journal ID (publisher-id): Drug Design, Development and Therapy
Title:
Drug Design, Development and Therapy
Publisher:
Dove Medical Press
ISSN
(Electronic):
1177-8881
Publication date Collection: 2017
Publication date
(Electronic):
08
December
2017
Volume: 11
Pages: 3519-3529
Affiliations
Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University,
Xuzhou, Jiangsu, People’s Republic of China
Author notes
Correspondence: Sheng Tan, Department of Thoracic Surgery, The Affiliated Hospital
of Xuzhou Medical University, Number 99 West Huaihai Road, Xuzhou, Jiangsu, 221000,
People’s Republic of China, Email
tanshengxzmu@
123456163.com
The full terms of this license are available at
https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0)
License (
http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work
are permitted without any further permission from Dove Medical Press Limited, provided
the work is properly attributed.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.